Synaptogenix, Inc. (NASDAQ:SNPX) Short Interest Update

Synaptogenix, Inc. (NASDAQ:SNPX) was the recipient of a large decline in short interest during the month of December. As of December 15th, there was short interest totalling 2,400 shares, a decline of 66.7% from the November 30th total of 7,200 shares. Based on an average daily volume of 22,600 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.2% of the company’s stock are short sold.

Synaptogenix Stock Performance

Synaptogenix stock traded down $0.02 during mid-day trading on Friday, reaching $3.28. The stock had a trading volume of 19,508 shares, compared to its average volume of 35,695. Synaptogenix has a one year low of $2.32 and a one year high of $8.78. The company has a 50-day moving average price of $2.91 and a two-hundred day moving average price of $3.43.

Synaptogenix (NASDAQ:SNPX) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($4.58) EPS for the quarter, missing analysts’ consensus estimates of ($1.95) by ($2.63).

About Synaptogenix

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.